Capstone Investment Advisors
ABCL icon

Capstone Investment Advisors’s AbCellera Biologics ABCL Stock Holding History

Capstone Investment Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,934
Closed -$70.6K – 2082
2023
Q2 		$70.6K Buy
+10,934
New +$74.6K ﹤0.01% 1740
2021
Q3 		– Sell
-65,005
Closed -$1.43M – 1997
2021
Q2 		$1.43M Buy
+65,005
New +$1.79M ﹤0.01% 1133

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capstone Investment Advisors's ABCL Position: Q3 2023 in Review

Capstone Investment Advisors sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 10,934 shares — an estimated $70.6K sold.

Capstone Investment Advisors first reported a position in ABCL in Q2 2021 and held it in 2 quarters. The position peaked at $1.43M in Q2 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Capstone Investment Advisors reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Capstone Investment Advisors sold 10,934 AbCellera Biologics shares in Q3 2023, an estimated $70.6K.
  • Capstone Investment Advisors first reported a position in AbCellera Biologics in Q2 2021 and held it in 2 quarters.
  • Capstone Investment Advisors's AbCellera Biologics position peaked at $1.43M in Q2 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Capstone Investment Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.